Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for drug screen using zebrafish model and the compounds screened thereform

A technology of medicine and prodrug, applied in the field of drugs and candidate compounds for the treatment and/or prevention of myopia and/or keratoconus disease, which can solve problems such as blurred vision

Inactive Publication Date: 2015-03-04
DCB美国公司 +1
View PDF17 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, long-term use of atropine to control the progression of myopia can lead to side effects such as blurred vision, constipation, decreased sweating, trouble falling asleep, dizziness, drowsiness, dry mouth, nose, or skin, headache, loss of appetite, loss of taste, nausea, or nervousness

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for drug screen using zebrafish model and the compounds screened thereform
  • Methods for drug screen using zebrafish model and the compounds screened thereform
  • Methods for drug screen using zebrafish model and the compounds screened thereform

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0206] Materials and Methods

[0207] aquatic culture

[0208] Zebrafish were cultured and maintained according to previously established methods (References: Soules KA, Link BA. Morphogenesis of the anterior segment in the zebrafish eye. BMC Dev Biol 2005; 5:12). All experiments were performed with zebrafish of the Tuebingen AB strain, cultured at 28°C with a 14-hour light and 10-hour dark cycle and maintained by standard methods. These embryos are staged according to phenotypic criteria (number of somites) (ref: Kimmel CB, Ballard WW, Kimmel SR, et al. Stages of embryonic development of the zebrafish. Dev Dyn 1995; 203(3): 253- 310), and timed in hours after fertilization. Embryos were produced by natural pair mating as described in the Zebrafish Reference Manual (References: Westerfield M. The zebrafish Book; A Guide for the Laboratory Use of zebrafish (Brachydanio rerio). University of Oregon Press, Eugene, 2nd edition 300P ., 1993). For each mating, 4±5 pairs were set...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The disclosure relates to a platform of using zebrafish in screening candidates for treating and / or preventing myopia and keratoconus disease. The disclosure is mainly based on that Lumican, one of several SLRPs, plays an important role in the regulation of fibrillogenesis or the genes affecting the size of eyeballs in zebrafish, in addition to playing an important role in clinical myopia. Therefore, the disclosure uses the established zebrafish model to further identify the drugs affecting the expression of lumican and collagen fibrillogenesis, and / or the regulation of eyeball size. These drugs are potential candidates for treating myopia and / or keratoconus disease.

Description

technical field [0001] This invention claims priority to US Provisional Patent Application US 61 / 649,611 filed on May 21, 2012. [0002] The invention relates to a drug screening method using zebrafish as a model. In particular, the present invention relates to an identification of a method that affects the expression of Lumican and collagen fibrillogenesis and can be used to treat diseases regulated by the expression of Lumican and / or collagen fibrillogenesis. A method for a candidate compound for a disease, and a candidate compound identified thereby. Further, the method identifies drugs for the treatment and / or prevention of myopia and / or keratoconus disease. Background technique [0003] Myopia is the most common eye disease worldwide. In Western countries, the prevalence of myopia is about 16% to 27%, while in Asian countries it may be higher. For example, the prevalence of myopia among Singaporean Chinese is 82%. When the refractive error (refractive error) is equ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/16C07C259/04
CPCA61K31/353A61K31/4402A61K31/381A61K31/05A61K31/198A61K31/351A61K31/185A61K31/5377A61K31/541A61K31/65A61K31/4178A61K31/366A61K31/192A61K31/5415A61K31/4166A61K31/138A61K31/18A61K31/165A61K31/405A61K31/357A61K31/445A61K31/16A61K31/164A61K31/4439A61K31/416A61K31/4045A61K31/401A61K31/196A61P27/02A61P27/10A61P43/00A61K31/343C07C259/04Y02P20/55
Inventor 王一中
Owner DCB美国公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products